Toxicity and Survival for Metastatic Melanoma Patients Treated With Anti-PD1 Therapy and Radiation Treatment

被引：1
|
作者：
Mowery, Y. M. [1 ]
Patel, K. [2 ]
Olson, A. C. [1 ]
Khan, M. K. [2 ]
Salama, J. K. [1 ]
Salama, A. K. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 96卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2016.06.383
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
357
引用
收藏
页码：S158 / S159
页数：2
相关论文
共 50 条
  • [1] ANTI-PD1 THERAPY IN PATIENTS WITH METASTATIC MELANOMA: A SINGLE CENTRE EXPERIENCE
    Nguyen, B.
    Robinson, E.
    Arora, A.
    Sayed, A.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 65 - 65
  • [2] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    [J]. MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [3] Predicting the response to anti-PD1 therapy in metastatic melanoma
    Heinzerling, Lucie
    Kirchberger, Michael Constantin
    Walter, Lisa
    Schuler, Gerold
    [J]. TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S576 - S579
  • [4] Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands
    van der Kooij, M. K.
    Joosse, A.
    Speetjens, F. M.
    Hospers, G. A. P.
    Bisschop, C.
    de Groot, J. W. B.
    Koornstra, R.
    Blank, C. U.
    Kapiteijn, E.
    [J]. ACTA ONCOLOGICA, 2017, 56 (01) : 101 - 103
  • [5] Intralesional anti-PD1 treatment in patients with metastatic melanoma: The pilot study.
    Samoylenko, Igor
    Korotkova, Olga V.
    Zabotina, Tatiana
    Demidov, Lev V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [6] CIRCULATING TUMOR DNA AS A BIOMARKER IN METASTATIC MELANOMA PATIENTS TREATED WITH ANTI-PD1 ANTIBODIES
    Lee, J.
    Boyd, S.
    Tembe, V.
    Menzies, A.
    Long, G.
    Guminski, A.
    Kefford, R.
    Carlino, M.
    Rizos, H.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 48 - 49
  • [7] Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.
    Christiansen, Shelly Ann
    Swoboda, David
    Gardner, Kellie
    Rapisuwon, Suthee
    Atkins, Michael B.
    Gibney, Geoffrey Thomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma.
    Eroglu, Zeynep
    Kim, Dae Won
    Johnson, Douglas Buckner
    Algazi, Alain Patrick
    Munhoz, Rodrigo Ramella
    Liniker, Elizabeth
    Kong, Ben
    Khurana, Neharika
    Chmielowski, Bartosz
    Sosman, Jeffrey Alan
    Scolyer, Richard A.
    Carlino, Matteo S.
    Postow, Michael Andrew
    Hwu, Wen-Jen
    Long, Georgina V.
    Ribas, Antoni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] "Interchangeability" of anti-PD1 antibodies in patients (pts) with metastatic melanoma (mM)
    Kravchuk, Darya
    Fedyanin, Mikhail
    Rays, Anastasia
    Moiseenko, Fedor Vladimirovich
    Ivanilov, Kirill
    Popov, Vladimir
    Glazkova, Elena
    Chubenko, Viacheslav
    Levchenko, Evgeny
    Volkov, Nikita
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Anti-PD1 therapy increases peripheral blood NKT cells and chemokines in metastatic melanoma patients
    Hakanen, H.
    Hernberg, M.
    Makela, S.
    Yadav, B.
    Bruck, O.
    Juteau, S.
    Kohtamaki, L.
    Ilander, M.
    Mustjoki, S.
    Kreutzman, A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
12345